All In Biotech

Drug Trial Radar · NCT05199571

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

A 12-month, Open-label, Prospective, Multicenter, Interventional, Single-arm Study Assessing the Efficacy and Safety of Ofatumumab 20 mg Subcutaneous (s.c.) Injection in Relapsing Multiple Sclerosis (RMS) Patients in China

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

99

Actual

Start

Jul 22, 2022

Primary completion

Feb 13, 2025

Study completion Feb 13, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • OfatumumabBiological

    Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Annualized Relapse Rate (ARR) Based on Confirmed RelapsesTime frame: Baseline up to approximately 12 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Shenzhen, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Lanzhou, Gansu, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, China

  • Novartis Investigative Site

    Shenyang, Liaoning, China

  • Novartis Investigative Site

    Taiyuan, Shanxi, China

  • Novartis Investigative Site

    Ürümqi, Xinjiang, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.